Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats

Behavioural Brain Research

Volumn 186, Issue 2, 2008, Pages 197-207

  Enomoto, Takeshi ^a   Ishibashi, Tadashi ^a   Tokuda, Kumiko ^a   Ishiyama, Takeo ^a   Toma, Satoko ^a   Ito, Akira ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Antipsychotics; Learning and memory; Morris water maze; NMDA receptor antagonist; Radial arm maze; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; DIZOCILPINE; DRUG VEHICLE; HALOPERIDOL; LURASIDONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; RISPERIDONE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DIVING; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG POTENCY; ESCAPE BEHAVIOR; LEARNING DISORDER; MALE; MAZE TEST; MEMORY DISORDER; MORRIS WATER MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RADIAL ARM MAZE TEST; RAT; REFERENCE MEMORY; SCHIZOPHRENIA; WORKING MEMORY;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ISOINDOLES; LEARNING DISORDERS; MALE; MAZE LEARNING; MEMORY DISORDERS; RATS; RATS, WISTAR; REACTION TIME; SWIMMING; THIAZOLES;

EID: 36249000612     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2007.08.012     Document Type: Article

References (36)

1. Arnsten A.F.T. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology 174 (2004) 25-31
2. Boast C., Bartolomeo A.C., Morris H., and Moyer J.A. 5HT antagonists attenuate MK801-impaired radial arm maze performance in rats. Neurobiol Learn Mem 71 (1999) 259-271
3. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., and Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14 (1996) 87-96
4. Cain D.P. Testing the NMDA, long-term potentiation, and cholinergic hypotheses of spatial learning. Neurosci Biobehav Rev 22 (1998) 181-193
5. 2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats. Neuropsychopharmacology 31 (2006) 757-767
6. Carlsson A., Hansson L.O., Waters N., and Carlsson M.L. A glutamatergic deficiency model of schizophrenia. Br J Psychiatry 174 Suppl. 37 (1999) 2-6
7. D'Hooge R., and De Deyn P.P. Applications of the Morris water maze in the study of learning and memory. Behav Brain Res 36 (2001) 60-90
8. Enomoto T., Noda Y., Mouri A., Shin E.J., Wang D., Murai R., Hotta K., Furukawa H., Nitta A., Kim H.C., and Nabeshima T. Long-lasting impairment of associative learning is correlated with a dysfunction of N-methyl-d-aspartate-extracellular signaling-regulated kinase signaling in mice after withdrawal from repeated administration of phencyclidine. Mol Pharmacol 68 (2005) 1765-1774
9. Enomoto T., Osugi T., Satoh H., McIntosh T.K., and Nabeshima T. Pre-injury magnesium treatment prevents traumatic brain injury-induced hippocampal ERK activation, neuronal loss, and cognitive dysfunction in the radial-arm maze test. J Neurotrauma 22 (2005) 783-792
10. Enomoto T., Noda Y., and Nabeshima T. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. Methods Find Exp Clin Pharmacol 29 (2007) 291-301
11. Green M.F., Kern R.S., Braff D.L., and Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr Bull 26 (2000) 119-136
12. Ishibashi T., Horisawa T., Yabuuchi K., Tagashira R., and Ohno Y. Receptor binding characteristics of SM-13496, a novel atypical antipsychotic agent. Soc Neurosci Abst 894 (2002) 7
13. Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmcol, in press.
14. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148 (1991) 1301-1308
15. 1A receptors in spatial and aversive learning in the rat. Neuropharmacology 48 (2005) 830-852
16. 2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int J Neuropsychopharmacol 8 (2005) 315-327
17. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21 (1999) 106S-115S
18. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25 (1999) 233-255
19. 7 receptor antagonists SB-269970 and DR-4004 in autoshaping Pavlovian/instrumental learning task. Behav Brain Res 155 (2004) 275-282
20. 2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex. Neuropsychopharmacology 29 (2004) 1637-1647
21. Nilsson M., Carlsson A., and Carlsson M.L. Glycine and d-serine decrease MK-801-induced hyperactivity in mice. J Neural Transm 104 (1997) 1195-1205
22. Noda Y., Yamada K., Furukawa H., and Nabeshima T. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol 116 (1995) 2531-2537
23. Ogasa M., Kimura T., Boylan M., Guarino J., and Nakamura M. SM-13496 in patients with acute exacerbation of schizophrenia: a two-dose double-blind phase II comparison with placebo. Schizophr Res 60 (2003) 297
24. Ogawa S., Okuyama S., Araki H., Nakazato A., and Otomo S. A rat model of phencyclidine psychosis. Life Sci 55 (1994) 1605-1610
25. Okaichi H., Oshima Y., and Jarrard L.E. Scopolamine impairs both working and reference memory in rats: a replication and extension. Pharmacol Biochem Behav 34 (1989) 599-602
26. Ortega-Alvaro A., Gibert-Rahola J., and Mico J.A. Influence of chronic treatment with olanzapine, clozapine and scopolamine on performance of a learned 8-arm radial maze task in rats. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 104-111
27. Roth B.L., Hanizavareh S.M., and Blum A.E. Serotonin receptors highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychophamacology 174 (2004) 17-24
28. Sakamoto H., Ohno Y., Tokuda K., Horisawa T., Matsumoto K., and Nakamura M. Determination of the extrapyramidal side effects liability of SM-13496, a novel serotonin/dopamine antagonist (SDA)-type antipsychotic agent. Soc Neurosci Abst 747 (1997) 20
29. Sams-dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol 7 (1996) 3-23
30. Scatton B., Cohen C., Perrault G., Oblin A., Claustre Y., Schoemaker H., Sanger D.J., Rouquier L., and Porsolt R. The preclinical pharmacologic profile of tiapride. Eur Psychiatry 16 Suppl. 1 (2001) 29-34
31. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Gompel P.V., Lesage A.S., De Loore K., and Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124 (1996) 57-73
32. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., and Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28 (2003) 1400-1411
33. Sharma T., and Antonova L. Cognitive function in schizophrenia deficits, functional consequences, and future treatment. Psychiatr Clin North Am 26 (2003) 25-40
34. Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in the Morris water maze. Psychopharmacology 124 (1996) 126-133
35. 1 receptor antagonist-induced spatial memory deficits in rats. Eur J Pharmacol 423 (2001) 167-170
36. Woodward N.D., Purdon S.E., Meltzer H.Y., and Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8 (2005) 457-472